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Conflicts of interest in medicine have received significant attention in recent years, through the public and professional
media, federal and state governments, and through a 2009 report of the Institute of Medicine on Conflict of Interest in
Medical Research, Education and Practice. The Council ofMedical Specialty Societies (CMSS) Code for Interactions with
Companies was adopted by the CMSS in April 2010. The Code guides specialty societies in the profession of medicine in
ethical relationships between societies and the pharmaceutical and medical device industries. The Code serves to protect
and promote the independence of specialty societies and their leaders in corporate sponsorships, licensing, advertising,

































OIn April 2010, the Council of Medical Specialty Soci-
eties (CMSS) assumed a unique role in professional self-
regulation with the adoption of its Code for Interactions
with Companies.
Several codes guiding relationships between the profes-
sion and the pharmaceutical and medical device industries
predated the CMSS Code. Ethical Opinions of the Council
on Ethical and Judicial Affairs (CEJA) of the American
Medical Association (AMA) have guided the ethical behav-
ior of physicians for decades. Two AMA CEJA Ethical
Opinions in particular are germane to relationships be-
tween the profession and industry: 8.061 – Gifts to Physi-
cians from Industry, and 9.011  Continuing Medical
Education.1
In 2002, the American Board of Internal Medicine
Foundation, the American College of Physicians Founda-
tion, and the European Federation of Internal Medicine
released “Medical Professionalism in the NewMillennium:
A Physician Charter,” which outlined professional obliga-
tions in the context of the social contract.2
In 2004, the Accreditation Council for Continuing
Medical Education (ACCME) revised and released the
Standards for Commercial Support: Standards to Ensure
the Independence of Continuing Medical Education
(CME) Activities.3 These standards have been adopted by
all CME accrediting and credit granting organizations in
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34She U.S., as well as by those in nursing, pharmacy, and
ptometry.
The Association of American Medical Colleges
AAMC) in 2008 published its task force report “Industry
unding of Medical Education.”4 In response, medical
chools and academic health centers have adopted their
wn codes to guide the relationships with industry of their
nstitutions, faculty, and employees.
The PhRMA Code on Interactions with Healthcare
rofessionals, produced by the Pharmaceutical Research
nd Manufacturers of America (PhRMA), was revised in
008 and released in January of 2009.5 This guidance is
irected toward employees of pharmaceutical companies.
o the degree that physicians are considered employees or
gents of pharmaceutical companies, this code would guide
he behavior of such physicians. In particular, members of
ompany speakers’ bureaus are identified in the PhRMA
ode as agents of companies.
The AdvaMed Code of Ethics on Interactions with
ealthcare Professionals, revised and released in 2009 by
he Advanced Medical Technology Association, guides the
ehavior of representatives of the medical device industry.6
he PhRMA and AdvaMed Codes are similar, with the
atter including guidance on training on new medical de-
ices unique to that industry.
Until the CMSS Code, however, there was no codified
ational guidance directed toward helping specialty societ-
es in the profession of medicine manage their relationships
ith the pharmaceutical and medical device manufacturers
o avoid, and when unavoidable, manage, relationships
hich result in conflicts of interest.
ROFESSIONALISM AND THE COUNCIL OF
EDICAL SPECIALTY SOCIETIES
Created in 1965, CMSS represents 37 specialty societ-
es in Medicine whose aggregate membership exceeds
50,000 practicing physicians in the U.S. (CMSS Member
rganizations include American Academy of Allergy,
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Volume 54, Number 18S Kahn and Lichter 35SDermatology [AAD]; American Academy of Family Physi-
cians [AAFP]; American Academy ofHospice and Palliative
Medicine [AAHPM]; American Academy of Neurology
[AAN]; American Academy of Ophthalmology [AAO];
American Academy of Otolaryngology-Head and Neck
Surgery [AAOHNS]; American Academy of Pediatrics
[AAP]; American Academy of Physical Medicine & Reha-
bilitation [AAPMR]; American College of Cardiology
[ACC]; American College of Chest Physicians [ACCP];
American College of Emergency Physicians [ACEP];
American College ofMedical Genetics [ACMG]; American
College of Obstetricians & Gynecologists [ACOG]; Amer-
ican College of Occupational and Environmental Medicine
[ACOEM]; American College of Physicians [ACP]; Amer-
ican College of Preventive Medicine [ACPM]; American
College of Radiology [ACR]; American College of Sur-
geons [ACS]; American Geriatrics Society [AGS]; Ameri-
can Medical Informatics Association [AMIA]; American
Psychiatric Association [APA]; American Society for Clin-
ical Pathology [ASCP]; American Society of Hematology
[ASH]; American Society for Reproductive Medicine
[ASRM]; American Society for Radiation Oncology
[ASTRO]; American Society of Clinical Oncology [ASCO];
American Society of Colon and Rectal Surgeons [ASCRS];
American Society of Plastic Surgeons [ASPS]; American
Urological Association [AUA]; North American Spine So-
ciety [NASS]; Society of Critical Care Medicine [SCCM];
Society for Hospital Medicine [SHM]; Society of Neuro-
logical Surgeons [SNS]; Society of Nuclear Medicine
[SNM]; Society of Thoracic Surgeons [STS]). In addition,
CMSS enjoys nine Associate Members which, while not
specialty societies, are national organizations that share
goals with CMSS (CMSS Associate Member Organiza-
tions include Association of American Medical Colleges
[AAMC]; American Board of Medical Specialties [ABMS];
Accreditation Council for Continuing Medical Education
[ACCME]; Accreditation Council for Graduate Medical
Education [ACGME]; Alliance for Continuing Medical
Education [ACME]; Association for Hospital Medical Ed-
ucation [AHME]; American Medical Association [AMA];
Federation of State Medical Boards [FSMB]; National
Board of Medical Examiners [NBME]).
CMSS operates under three strategic priorities: to con-
vene members around issues of mutual interest, to facilitate
a Culture of Performance Improvement in medical prac-
tice, and to model Professionalism. It is the latter priority
which stimulated the development of the CMSS Code for
Interactions with Companies.
CMSS uses a working definition of Professionalism
which includes:
● Altruism (ensuring that the needs of patients come
first)
● Self-regulation
● Transparency (to peers, patients, and the public)
The CMSS Code reflects all three attributes of Profes-
sionalism. The Code insists on transparency of relationships
of the society, as well as of the society’s key leaders with industry. The Code is the Profession’s self-regulatory guid-
nce, voluntarily adopted. The Code focuses on avoiding,
nd when unavoidable, managing, disclosed relationships
o prioritize patient benefits over physician benefits.
HE PERCEIVED FAILURE OF
ROFESSIONALISM
In just the past 3 years, the medical profession has
uffered from numerous examples of reaction to society’s
erception of physicians prioritizing professional relation-
hips with industry over patient benefits. Lucrative physi-
ian relationships with industry have been the subject of
ntense media coverage. Society relationships with industry
ave been challenged in the professional media, as well as in
he public media. Laws have been passed in states requiring
isclosure, or banning specific relationships between phy-
icians and industry.
Society has several groups which serve as “watchdogs”
ver professions. These groups do not hesitate to publically
isclose and challenge relationships which appear to violate
ne of the three tenets of professionalism. These social
watchdogs” include:
. National and local media (recently theNew York Times7
and others)
. Professional media (Journal of the American Medical
Association [JAMA] articles challenging specialty soci-
eties, among others, on their relationships with indus-
try8,9)
. Professional associations (notably the Institute of Med-
icine of the National Academy of Sciences10)
. Executive branch of the federal government (notably
the Food and Drug Administration [FDA] and the
Office of the Inspector General of the Department of
Health and Human Services [OIG]11)
. Legislative branch of the federal government (currently
the Senate Finance Committee and Special Committee
on Aging)
. State government (regulatory laws in Massachusetts,
Vermont, New York, Minnesota, and other states pro-
hibiting or limiting certain direct financial relationships
between physician and industry)
At the Federal level, the Physician Payments Sunshine
ct (PPSA), requiring pharmaceutical and medical device
anufacturers to disclose payments to physicians, was ad-
pted in the spring of 2009 as part of the Affordable Care
ct.12 Failure of a profession to self-regulate, in this case
he profession of medicine, results in these natural conse-
uences leading to external regulation. In the spirit of
ransparency, CMSS supported the PPSA, noting that this
aw requires only disclosure. It remains the responsibility of
he profession of medicine to determine appropriate rela-
ionships with industry, all of which are to be disclosed, and
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INTERACTIONS WITH COMPANIES
In the spring of 2008, the assembled chief executive
officers of the CMSSmember organizations recognized the
growing perception that certain relationships between the
profession and industry were threatening professional self-
regulation. In response, CMSS convened a Task Force on
Professionalism and Conflict of Interest, which made the
following recommendations that were adopted by CMSS in
the fall of 2008:
Recommendation (1) – it is recommended that the
following core principles be considered by specialty societ-
ies for incorporation into conflict of interest policies:
a. Definitions of conflict of interest, including financial
and fiduciary, whether considered “real” or “per-
ceived”;
b. Clarification of who is addressed in the society’s policy,
including elected leaders, volunteers, representatives,
members, staff, and the society itself;
c. Delineation of activities addressed in the policy, includ-
ing governance; undergraduate, graduate, and continu-
ing medical education; research; and clinical practice
guideline development;
d. Examples of conflicts of interest addressed in the policy;
e. Disclosures of relationships addressed in the policy,
including criteria for disclosure, and manner of disclo-
sure (written, verbal, Web, other);
f. Consequences for failure to disclose relationships with a
“real” or “perceived” conflict of interest;
g. Management and resolution strategies for disclosed
conflicts of interest;
h. Clarification of circumstances requiring recusal, re-
moval from participation, or from the disclosed rela-
tionship;
i. Adherence to external standards and guidelines, such as
the ACCME Standards for Commercial Support of
CME, the AMA Ethical Opinion on Gifts to Physicians
from Industry, and potentially others.
Recommendation (2) – it is recommended that specialty
societies consider publically disclosing on their Web sites
the following information:
a. Society Conflict of Interest Policies;
b. Financial support received by the society from commer-
cial interests;
c. Society endorsements of external policies related to
Conflict of Interest (such as the ACCME Standards for
Commercial Support of CME, the AMA Ethical Opin-
ion on Gifts to Physicians from Industry, and potentially
others).
Recommendation (3) – it is recommended that CMSS
consider developing standardized model templates of con-
flict of interest policies, disclosure forms, and potentially
management and resolution strategies, for use by specialty
societies.Not satisfied that these recommendations were suffi-
ient, in the Spring of 2009, the chief executive officers of
he CMSS member organizations recommended that
MSS definitively craft a Code to serve as a guide for
pecialty societies in relationships with industry. All CMSS
ember and associate members were invited to participate
n the new task force, in which 36 organizational represen-
atives ultimately participated, including amixture of senior
taff, general counsels, CEOs, and volunteer physician lead-
rs. The group met in person, conducted conference calls
nd electronic communication, and produced a draft Code
y the Fall of 2009.
At the CMSS Annual Meeting in November of 2009,
n open discussion forum was held with more than 130
articipants from specialty societies. Invited guest panelists
ncluded the Chair of the Institute of Medicine Committee
n Conflict of Interest in Medical Research, Education and
ractice; the Vice-chair of the AMACouncil on Ethical and
udicial Affairs; and the General Counsel of PhRMA.
Controversial elements of the 2009 draft Code in-
luded the management of Satellite CME programs (de-
ned as “. . . a Company-supported CME program held as
n adjunct to a Society meeting where CME credit for the
ymposium is provided by a third party CME provider, and
or which the Society receives a fee”), permitting some
embers of clinical guideline panels to have certain rela-
ionships with industry, and appropriate management of
ndustry relationships of “key society leaders” (defined as
he President-elect, President, Immediate Past-president,
hief Executive Officer, and Editor-In-Chief of the soci-
ty’s journal). Subsequent to the CMSS annual meeting,
he task force met once more in early 2010, and recom-
ended that a revised Code be voted upon at the CMSS
pring meeting, April 17, 2010, where the Code was ad-
pted.
RINCIPLES OF THE CMSS CODE FOR
NTERACTIONS WITH COMPANIES
I. Preamble
The CMSS Code reinforces the core principles that
specialty societies must maintain actual and perceived
independence in all their activities and decisions, and
that such activities lead to improvement of care for
patients in the various specialty fields.
II. About the Code
The stated purpose of the Code is to guide specialty
societies in the development of policies and procedures
that safeguard the independence of their programs and
positions. Societies may adopt policies that are more
stringent than those found in the CMSS Code.
II. Definitions
Sixteen relevant terms are defined in the Code, using,
when available, consistent definitions from similar ex-
tant codes guiding interactions between physicians
and industry. Such other codes include the ethical
opinions of the Council on Ethical and Judicial Affairs
of the American Medical Association,1 the Standards
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Independence of CME Activities of the ACCME,3 the
Code of Ethics on Interactions with Healthcare Pro-
fessionals of the Advanced Medical Technology Asso-
ciation,6 and the Code on Interactions with Health-
care Professionals of the Pharmaceutical Research and
Manufacturers of America.5 Notably, the definition of
a company is drawn from that shared by ACCME3 and
AdvaMed6:
. . . a for-profit entity that develops, produces, markets, or
distributes drugs, devices, services or therapies used to
diagnose, treat, monitor, manage, and alleviate health
conditions. This definition is not intended to include
non-profit entities, entities outside of the health care
sector, or entities through which physicians provide clin-
ical services directly to patients. However, a Society may
choose to adopt a broader definition of “Company” if
doing so would better address the Society’s interactions.
IV. Principles for interaction
Herein are summarized the guidance for 10 major categories
of interactions between specialty societies and industry
1. Independence (Five Code elements)
Societies signing on to the CMSS Code will develop all
programs, products, services, and policy positions inde-
pendent of any influence of any company with which the
society has a relationship. In addition, societies will iden-
tify an internal group responsible for monitoring and
guiding society interactions with companies.
The most controversial element of this section, and
indeed of the entire Code, is element 1.4, here described
verbatim:
No Key Society Leader, defined for purposes of this Code
as the Presidential line of succession of a Society’s mem-
bership organization (eg, the President, President-elect,
and Immediate Past President), the chief executive officer
of a Society’s membership organization, and the Edi-
tor(s)-in-Chief of Society Journal(s), may have Direct
Financial Relationships with Companies during his or her
term of service.
In this case, direct financial relationships with companies
are defined to mean relationships resulting in an IRS form
1099, such as consultancies, serving on a company speak-
ers’ bureau, and similar relationships. Relationships ex-
cluded from this prohibition include modest stock own-
ership, as well as serving as an employee of a company for
the purpose of providing direct patient care to employees
of the company. CMSS has come to recognize that, in
addition, there are certain unique relationships that can-
not be divested, such as a physician who owns a patent
from which the physician receives royalty payments.
The rationale for this element is the recognition that
most, but not all relationships between physicians and
industry can be managed internally through appropriate
disclosure and management of the disclosed conflict. An
exception may be in the society president, whose repre-
sentation of the society extends externally. It is the societypresident, for example, who usually responds to requests
for media interviews. Similarly, should the society gain an
audience with congressional leaders, it is the President
who usually represents the society. In such external repre-
sentations, the society is cautioned from setting up a
situation where a significant relationship between the
society leader and industry, even openly disclosed, be-
comes the focus of the interview or representation, result-
ing in inadvertent dilution or abatement of the society’s
intended message.
2. Transparency (Three Code elements)
Societies signing on to the CMSS Code will publicize
their conflict of interest policies and forms, disclose sup-
port received from companies, adopt disclosure policies
for society leadership, and use the disclosed information
to manage conflicts of interest on an on-going basis.
3. Accepting Charitable Contributions (Five Code ele-
ments)
Societies signing on to the CMSS Code will align charita-
ble contributions with the society’s mission, and will not
accept contributions from donors which expect to influ-
ence society programs or positions, or when the donation
is not consistent with the society mission.
4. Accepting Corporate Sponsorships (Four Code elements)
Corporate sponsorship is defined in the Code as
. . . an arrangement in which a Company, typically
through its marketing department, provides monetary or
in-kind support for a particular Society product, service,
or event, and is then acknowledged in connection with
the product, service, or event. Corporate Sponsorships
are distinct from Educational Grants, and do not consti-
tute Commercial Support of CME. For purposes of this
Code, Corporate Sponsor refers to a Company that pro-
vides a Corporate Sponsorship.
Societies signing on to the CMSS Code will only accept
corporate sponsorships for items or programs aligned with
the society’s mission. Consistent with the PhRMA5 and
AdvaMed6 Codes, the CMSS Code prohibits company
names or logos from “reminder” items at meetings, such
as lanyards and tote bags.
A unique element of this section of the Code chal-
lenges societies to “make reasonable efforts” to seek mul-
tiple sponsors. The rationale for this guidance is that a
single corporate sponsor may be more likely to be per-
ceived by an observer as more at risk of influencing the
society than would a group of competitors sharing spon-
sorship of an item or program.
The final element of this section prohibits corporate
sponsors of a society data registry from any participation in
the management of the registry.
5. Society Meetings
5.1. Educational Grants and Society CME (Seven Code
elements)
Significantly, the first entry in this section continues
the pattern of consistency between the CMSS Code
and other current self-regulatory standards of the
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ies signing on to the CMSS Code will:
. . . comply with ACCME Standards for Commercial
Support, including by adopting policies and procedures
designed to identify and manage conflicts of interest in
Company-supported Society CME programs.
Adopting and rigorously enforcing these policies pre-
cludes Company influence over Society CME content.
The elements in this section include controlling
educational grants; appointing all planning commit-
tees; assuring that programs are free from commer-
cial bias, including prohibiting the use of company
controlled presentation materials and slides; not so-
liciting content or speaker suggestions from corpo-
rate supporters; not seeking support for product
specific topics; and requiring presenters to incorpo-
rate balanced recommendations and use generic
names of pharmaceutical agents.
One element in this section deserves particular
attention, in recommending that societies signing on
to the CMSS Code “make reasonable efforts to
achieve a balanced portfolio of support for each
society program.” The rationale behind this guid-
ance is to minimize the perception of corporate
influence by disclosing support not only from multi-
ple competitors within an industry, but additionally
through disclosing support from multiple sources,
including companies, foundations, and tuition from
attendees.
5.2. CME-accredited satellite symposia (Five Code ele-
ments)
Satellite CME Symposia are defined as:
. . . a Company-supported CME program held as an ad-
junct to a Society meeting where CME credit for the
Symposium is provided by a third party CME provider,
and for which the Society receives a fee.
Satellite CME symposia have been controversial
among specialty societies. Satellite programs are held
in conjunction with society annual CMEmeetings in
order to attract the attendees, yet the programs are
neither provided nor controlled by the societies, but
rather by a third-party provider which is funded by a
corporate supporter. As such, these symposia may
give the impression of being offered by the society
when they are not, and worse, of being influenced by
the single corporate supporter, as the faculty mem-
bers are often drawn from the speakers’ bureaus of
the corporate supporter.
This set of elements of the Code guides societies
to exert control over satellite CME symposia
through an application and review process, requiring
the accredited CME provider to comply with the
ACCME Standards for Commercial Support,3 and
to utilize four best practices to minimize the poten-
tial for bias:1. Requiring presentations to be evidence-based;
2. Requiring peer review of slide presentations in ad-
vance;
3. Prohibiting presenters who disclose unmanageable
conflicts from making practice recommendations.
These presenters may present on general topics only
(eg, pathophysiology, research data). An additional
speaker without unmanageable conflicts may be added
to the program to make practice recommendations.
4. Requiring presentations to be monitored by reviewers
trained to recognize bias.
Further, societies will ensure that satellite CME pro-
viders distinguish satellite programs from society CME
in brochures and promotional materials. Moreover,
societies are cautioned not to permit Key Society Lead-
ers to participate as faculty in satellite CME symposia,
so as to reduce the misperception that such programs
are part of the society’s CME programming.
4.3. Non-CME informational/educational programs
(One Code element)
Should a society offer an informational program
which does not carry CME credit, such a program
must be clearly distinguished, in location and sig-
nage, from society CME.
4.4. Exhibits (Four Code elements)
Societies signing on to the CMSS Code will comply
with all applicable laws (ie, state laws), regulations
(ie, FDA), and guidance (ie, PhRMA5 and Ad-
vaMed6 Codes). Included in such guidance is the
prohibition of “giveaways” that are not educational
in nature, and are of more than “modest” value. The
Code goes a step further than other guidance in
asking societies to make reasonable efforts to place
exhibit booths out of attendees “obligate pathway”
to society CME sessions. Again, Society Key Leaders
are prohibited from participating on behalf of compa-
nies in corporate exhibit booths, so as to avoid the
mixed message that would be sent by displaying such
physicians as agents of companies, rather than as society
leaders.
5. Awarding of research grants (Six Code clements)
Societies signing on to the CMSS Code will not permit
company influence in the process of selecting recipients of
research grants, but will rather appoint independent com-
mittees for such purpose. Further, recipients of research
grants will not be permitted to meet with corporate sup-
porters, nor to agree to intellectual property rights or
royalties arising from the supported research. Companies
supporting researchmay not influence manuscripts arising
from the research.
6. Clinical practice guidelines (15 Code elements)
The largest section of the CMSS Code is devoted to the
creation of clinical practice guidelines, which are to be
developed through a transparent process that is free of
both corporate support and influence. Guideline panel
members and society staff may not discuss a guideline’s
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review draft guidelines.
The Code further reinforces the importance of basing
clinical practice guidelines on scientific evidence, rigorous
peer review, and review by the society’s board of directors
or another body to which the board of directors delegates
such review. Prior to publication, guidelines are to be
submitted to independent review by the journal in which
the guidelines are first published.
Members of guideline panels and other contributors are
to disclose all relationships relevant to panel deliberations,
and importantly to update such disclosure on an on-going
basis throughout the process. A majority of panel mem-
bers are to be free of relationships constituting a conflict of
interest, as well as the panel Chair, who must remain free
of such conflicts of interest for at least a year following
publication of the guideline. The disclosure information
of panel members will be published adjacent to the guide-
line, including abstentions from voting.
Guideline panel members are not to speak about the
guideline on behalf of affected companies for a reasonable
period, to be determined by the society, after guideline
publication.
8. Society journals (Five Code elements)
The CMSS Code references the guidance promulgated in
2009 by the International Committee of Medical Journal
Editors (ICMJE),13 and theWorld Association ofMedical
Editors.14 Societies signing on to the CMSS Code will
ensure that their journal(s) are independent from adver-
tisers. Authors, reviewers, and editors must disclose all
relationships with companies (as a Key Society Leader, the
Editor-in-Chief may not have any such relationships with
companies). Society journals will prohibit “ghost written”
manuscripts prepared by or on behalf of companies.
9. Standards for advertising (One Code element)
Societies signing on to the CMSS Code will adopt adver-
tising standards that include distinguishing advertise-
ments from editorial content, and prohibiting placement
of advertisements adjacent to editorial content discussing
the subject of the advertisement.
10. Standards for licensing (One Code element)
Societies signing on to the CMSS Code will prohibit
misuse and modification of licensed materials, as well as
use of society trademarks to imply society endorsement
of company products or services.
V. Adherence to the Code
Adoption of the CMSS Code by specialty societies is voluntary
for both CMSS member societies and nonmembers. Societies
that sign on to the CMSS Code are expected, within a reason-
able time frame, to adopt policies that are consistent with the
Code. Societies are free to adopt policies which are more
rigorous than those found in the CMSS Code.
While CMSS will not enforce the Code, societies signing
on to the Code and annually certifying their continued
adherence to the Code will be identified on the CMSS Web
site.IGNERS TO THE CMSS CODE
As of July 25, 2011, 40 organizations have signed on to
he CMSS Code, including 26 CMSS member organiza-
ions (70%), nine nonmember societies, and five CMSS
ssociate Member organizations that have expressed sup-
ort for the Code. Additional signers are anticipated in
011 as editorial clarifications to the Code are published
ollowing the CMSS spring meeting, March 19, 2011.
MPLICATIONS OF THE CODE
For the first time, specialty societies in the profession of
edicine have national guidance to help them avoid, and
here unavoidable, manage relationships with industry
hich create conflicts of interest. Organizations adopting
he CMSS Code will establish policies and procedures
hich will protect the society, its leaders and members, and
ltimately their patients by enhancing the fulfillment of
rofessionalism. Relationships between societies and indus-
ry will be transparent. Relationships between society key
eaders and industry will be minimized so as to avoid the
erception of conflict of interest in their roles as national
epresentatives of their society and specialty. Society spon-
ored CME programming and clinical practice guidelines
ill be, actually and perceived, independent from industry
nfluence. Physicians benefitting from society CME or fol-
owing society practice guidelines will provide evidence-
ased care, resulting in improved patient outcomes. The
rofession of medicine will be perceived as self-regulating
n a controversial ethical area, to the ultimate benefit of
atients.
The authors would like to thank Dina Michaels, JD,
eneral Counsel, and Courtney Storm, JD, Associate Gen-
ral Counsel, American Society of Clinical Oncology, for
heir work in supporting the CMSS Task Force on Profes-
ionalism and Conflict of Interest, which developed the
MSS Code for Interactions with Companies.
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